文献速递心力衰竭与心肌病

慢性肾脏病中发生心力衰竭:蛋白质组学揭示生物学机制与风险分层

Incident heart failure in chronic kidney disease: proteomics informs biology and risk stratification.
PubMed 文献 · Eur Heart J · 2024-01-01

该研究在慢性肾脏病(CKD)人群中分析SomaScan V4.0检测的4638种蛋白质,主要结局为14年内心力衰竭(HF)发生(390例事件),并在ARIC研究中验证。结果发现超过200种蛋白质与HF发生相关,孟德尔随机化提示6种蛋白有因果关联,其中4种为可成药靶点;48蛋白风险模型在CRIC中的C统计量为0.790,优于PCP-HF模型的0.703。

要点

  • CKD人群大规模蛋白质组学可发现与心力衰竭发生相关的新循环蛋白标志物。
  • 48蛋白风险模型在CRIC中预测14年HF的C统计量为0.790,优于PCP-HF的0.703。
  • 孟德尔随机化提示6种蛋白与HF有因果关联,其中FCG2B、IGFBP3、CAH6、ASGR1为可成药靶点。

核心结论

  • 大规模蛋白质组学在CKD人群中揭示了新的循环蛋白生物标志物及HF的潜在介质。
  • 蛋白质组风险模型在该人群中改善了PCP-HF风险评分的预测性能。

研究设计与样本

  • 研究分析了慢性肾脏病队列(CRIC)2906名参与者的SomaScan V4.0(4638种蛋白质),并在ARIC研究中进行验证。
  • 主要结局为14年内心力衰竭发生(390例事件),次要结局包括4年HF(183例事件)、射血分数降低的HF(137例事件)和射血分数保留的HF(165例事件)。
  • 应用孟德尔随机化和基因本体论分析因果性与通路,并将新型多蛋白风险模型与PCP-HF风险评分进行比较。

主要发现

  • 调整估计肾小球滤过率后,超过200种蛋白质与心力衰竭发生相关(P < 1 × 10-5)。
  • 进一步调整包括N末端B型利钠肽原在内的协变量后,17种蛋白质仍保持相关(P < 1 × 10-5)。
  • 孟德尔随机化发现6种蛋白质与HF存在关联,其中FCG2B、IGFBP3、CAH6和ASGR1为可成药靶点。
  • 主要结局中,48蛋白模型在CRIC的C统计量(95%CI)为0.790(0.735, 0.844),PCP-HF模型为0.703(0.644, 0.762)(P = .001)。
  • 蛋白质模型在ARIC中的C统计量(95%CI)为0.747(0.707, 0.787)。

临床怎么用

  • 在CKD人群中,可考虑基于蛋白质组学的风险模型来改善心力衰竭风险分层,其预测性能优于PCP-HF评分。
  • FCG2B、IGFBP3、CAH6和ASGR1等可成药蛋白靶点可能为心力衰竭预防提供新方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Incident heart failure (HF) among individuals with chronic kidney disease (CKD) incurs hospitalizations that burden patients and health care systems. There are few preventative therapies, and the Pooled Cohort equations to Prevent Heart Failure (PCP-HF) perform poorly in the setting of CKD. New drug targets and better risk stratification are urgently needed. METHODS: In this analysis of incident HF, SomaScan V4.0 (4638 proteins) was analysed in 2906 participants of the Chronic Renal Insufficiency Cohort (CRIC) with validation in the Atherosclerosis Risk in Communities (ARIC) study. The primary outcome was 14-year incident HF (390 events); secondary outcomes included 4-year HF (183 events), HF with reduced ejection fraction (137 events), and HF with preserved ejection fraction (165 events). Mendelian randomization and Gene Ontology were applied to examine causality and pathways. The performance of novel multi-protein risk models was compared to the PCP-HF risk score. RESULTS: Over 200 proteins were associated with incident HF after adjustment for estimated glomerular filtration rate at P < 1 × 10-5. After adjustment for covariates including N-terminal pro-B-type natriuretic peptide, 17 proteins remained associated at P < 1 × 10-5. Mendelian randomization associations were found for six proteins, of which four are druggable targets: FCG2B, IGFBP3, CAH6, and ASGR1. For the primary outcome, the C-statistic (95% confidence interval [CI]) for the 48-protein model in CRIC was 0.790 (0.735, 0.844) vs. 0.703 (0.644, 0.762) for the PCP-HF model (P = .001). C-statistic (95% CI) for the protein model in ARIC was 0.747 (0.707, 0.787). CONCLUSIONS: Large-scale proteomics reveal novel circulating protein biomarkers and potential mediators of HF in CKD. Proteomic risk models improve upon the PCP-HF risk score in this population.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Dubin, Deo, Ren, et al. Incident heart failure in chronic kidney disease: proteomics informs biology and risk stratification. Eur Heart J. 2024. PMID: 38757788. doi:10.1093/eurheartj/ehae288

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。